Intravenous Administration of Nifekalant Hydrochloride for the Prevention of Ischemia-Induced Ventricular Tachyarrhythmia in Patients With Renal Failure Undergoing Hemodialysis

Masafumi Myoishi; Satoshi Yasuda; Shunichi Miyazaki; Kazuyuki Ueno; Isao Morii; Kazuhiro Satomi; Yoritaka Otsuka; Atsushi Kawamura; Takashi Kurita; Shiro Kamakura; Hiroshi Nonogi

doi:10.1253/circj.67.898

Rapid Communication

Intravenous Administration of Nifekalant Hydrochloride for the Prevention of Ischemia-Induced Ventricular Tachyarrhythmia in Patients With Renal Failure Undergoing Hemodialysis

Masafumi Myoishi, Satoshi Yasuda, Shunichi Miyazaki, Kazuyuki Ueno, Isao Morii, Kazuhiro Satomi, Yoritaka Otsuka, Atsushi Kawamura, Takashi Kurita, Shiro Kamakura, Hiroshi Nonogi

Author information

Keywords: Antiarrhythmic agents, Hemodialysis, Ventricular tachyarrhythmia

JOURNAL FREE ACCESS

2003 Volume 67 Issue 10 Pages 898-900

DOI https://doi.org/10.1253/circj.67.898

Details

Abstract

Excretion in the urine is an important pathway for the elimination of nifekalant hydrochloride (NIF), a novel class III antiarrhythmic agent. Three patients with renal failure were undergoing hemodialysis and receiving NIF for the prevention of ischemia-induced ventricular tachyarrhythmia. Because NIF is not dialyzed, dose adjustment at relatively low concentrations was required, with monitoring of the QT interval. (Circ J 2003; 67: 898 - 900)

Corresponding author

Register with J-STAGE for free!